An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that healthcare-associated invasive methicillin-resistant Staphylococcus aureus (MRSA) infections decreased among patients with infections that began in the community or in the hospital, according to a study in the Aug. 11 issue of JAMA.
An estimated 1.7 million healthcare-associated infections (HAIs) are associated annually with 99,000 deaths in U.S. hospitals. A multidrug-resistant organism that has received much attention is MRSA, and preventing healthcare-associated MRSA infections has become a goal for public health agencies and policy makers, with prevention programs increasingly common in health care settings. Whether there have been changes in MRSA infection incidence as these programs become established has not been known, according to background information in the article.
Alexander J. Kallen, MD, MPH, of the Centers for Disease Control and Prevention (CDC), and colleagues used a population-based surveillance system to evaluate the incidence of invasive healthcare-associated MRSA infections from 2005 through 2008 in nine metropolitan areas covering a population of approximately 15 million persons. All reports of laboratory-identified episodes of invasive (from a normally sterile body site such as the bloodstream) MRSA infections were evaluated and classified based on the setting of the positive culture and the presence or absence of healthcare exposures.
Overall, the participating surveillances sites reported 21,503 cases of invasive MRSA infections for the years 2005 through 2008, with 17,508 cases either hospital-onset or healthcare-associated community-onset. Most healthcare-associated infections (15,458 [88 percent]) involved a positive blood culture and were classified as a bloodstream infection (BSI).
The modeled incidence, adjusted for age and race, of hospital-onset invasive MRSA infections significantly decreased 9.4 percent per year from 2005 through 2008; while there was a significant 5.7 percent decrease per year in the modeled incidence of healthcare-associated community-onset infections. This would equate to about a 28 percent decrease in all hospital-onset invasive MRSA infections and about a 17 percent decrease in all invasive healthcare-associated community-onset infections over the four-year period, the authors write. four-year period. A subset analysis limited to BSIs demonstrated a larger decrease in the modeled yearly incidence rates of both hospital-onset (-11.2 percent) and healthcare-associated community-onset (-6.6 percent) BSIs, equating to about a 34 percent decrease in all hospital-onset MRSA BSIs and about a 20 percent decrease in all healthcare-associated community-onset BSIs over the
The researchers add that although the reasons for the observed decrease in incidence of invasive healthcare-associated MRSA infections are not known, a number of factors might have contributed, including the dissemination of MRSA prevention practices in many U.S. hospitals.
The researchers write, this evaluation demonstrates that the incidence of hospital-onset and healthcare-associated community-onset invasive MRSA infections has decreased dramatically and significantly in this large geographically diverse population. Taken together with data from more than 600 intensive care units nationwide, these findings suggest that there is a real decrease in MRSA infection rates among patients in U.S. hospitals. As highlighted in the recently finalized U.S. Department of Health and Human Services Action Plan to Prevent Healthcare-Associated Infections, prevention of invasive MRSA infections is a national priority. Although these data suggest progress has occurred in preventing healthcare-associated MRSA infections, more challenges remain. Increasing adherence to existing recommendations and addressing MRSA transmission and prevention beyond inpatient settings are challenges that will require further effort and investigation if eliminating the goal of preventable healthcare-associated invasive MRSA infections is to be attained.
In an accompanying editorial, "Decline in Invasive MRSA Infection Where to Go From Here?" Eli N. Perencevich, MD, MS, and Daniel J. Diekema, MD, of the University of Iowa Carver College of Medicine in Iowa City, comment on the findings of this study: The study by Kallen et al, when combined with previous investigations, suggests that there may be an ongoing decrease in MRSA as a cause of human infection, particularly in non-community settings. Although the present decrease in MRSA may be used to argue for or against MRSA-specific vs. general infection prevention interventions, these arguments would be missing the point. The decreases are occurring for a reason, and only by improving existing surveillance and prevention research programs can clinicians and infection control researchers begin to explain why. Such research will be essential for guiding future approaches to all S aureus prevention. Although MRSA may be in decline, it is unlikely that S aureus will follow suit.
Reference: JAMA. 2010;304[6]:641-648; JAMA. 2010;304[6]:687-689.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.